PDI Inc have entered into an agreement with Organogenesis Inc where PDI's Medical Devices & Diagnostics unit (PDI MD&D) will provide sales, marketing and clinical support for Apligraf, Organogenesis' living, bi-layered skin substitute.
PDI will leverage its wound care sales force and provide marketing resources in support of Apligraf. PDI InServe will utilize its current team of wound care nurses to provide after sales clinical support for practitioners. Under the terms of the agreement, PDI will receive a fee with the potential to earn incentives based on performance.
Apligraf is the first mass-produced product containing living human cells to gain FDA approval. Apligraf is approved to treat both diabetic ulcers and venous leg ulcers.
Apligraf is a registered trademark of Novartis.